EXAS vs SCM · rev $2.76B vs P/E 10, rev $97.8M
EXACT Sciences Corporation (EXAS) versus Stellus Capital Investment (SCM) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Stellus Capital Investment (SCM) is a asset management company listed on NYSE.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported SCM revenue for 2025-12-31 was $97.8M. Net income was $27.0M. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
EXAS currently screens at market cap $20.03B. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
Not investment advice. Open the EXAS and SCM stock pages for the full models.
Not investment advice.